One receptor, D2, was elevated, while another, D4, was reduced—whether the attention deficits resulted from parental neglect ...

Recently, timed-release bromocriptine (Cycloset), a sympatholytic dopamine D 2 receptor agonist, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of type 2 diabetes.

Dopamine’s effects in the brain are mediated by postsynaptic D1 and D2 receptors. Adenosine A1 and A2A receptors are uniquely positioned to counteract the excessive stimulation of dopamine receptors ...

University of Southern California-led researchers have discovered the structural details of a brain receptor called GPR6, which could lead to new treatments for Parkinson's disease. GPR6 is an ...

Intra-Cellular Therapies’ CAPLYTA is making waves in the antipsychotic market, gaining traction as a novel treatment for schizophrenia and bipolar depression. With its differentiated safety profile ...

1998). These five subtypes have been grouped into two different classes based on pharmacology and biochemistry: the D1-like and the D2-like receptors. The D1-like receptors, D1 and D5, mediate ...

Striatal dopamine (DA) release regulates reward-related learning and behavioural activation and is believed to consist of a short-lived phasic and continuous tonic component. Here, we build a ...